Plus TherapeuticsPSTV
PSTV
About: Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
Employees: 20
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
0.11% more ownership
Funds ownership: 11.38% [Q3] → 11.49% (+0.11%) [Q4]
0% more funds holding
Funds holding: 10 [Q3] → 10 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
20% less capital invested
Capital invested by funds: $981K [Q3] → $780K (-$201K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for PSTV.
Financial journalist opinion
Based on 11 articles about PSTV published over the past 30 days
Neutral
Accesswire
2 days ago
D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement
HOUSTON, TX / ACCESS Newswire / March 11, 2025 / On March 4th, Plus Therapeutics, Inc. (Nasdaq:PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. "This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies," said Marc H.
Neutral
GlobeNewsWire
3 days ago
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
HOUSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq's minimum stockholders' equity requirement. The Company's common stock will continue to be listed and traded on The Nasdaq Capital Market.
Positive
Zacks Investment Research
6 days ago
PSTV Stock Skyrockets on FDA's Orphan Drug Tag for Cancer Therapy
The FDA bestows an Orphan Drug tag to Plus Therapeutics' investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in lung cancer patients.
Neutral
GlobeNewsWire
6 days ago
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
Rhenium ( 186 Re) Obisbemeda demonstrates safety, response, and potential efficacy for glioblastoma (GBM) patients Patients receiving >100 Gy of Rhenium ( 186 Re) Obisbemeda achieved a median overall survival of 17 months, more than double the 8-month median overall survival with standard of care HOUSTON, March 07, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the publication of results in a peer-reviewed manuscript titled, "Treatment of Recurrent Glioma by Rhenium (186Re) Obisbemeda (186RNL): a Phase 1 clinical trial" in the peer-reviewed medical journal Nature Communications. “Peer-reviewed publication of our Phase 1 glioma data in a prestigious, high-impact factor journal is substantial validation for this important clinical program,” said Marc H.
Neutral
GlobeNewsWire
1 week ago
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with L
Neutral
GlobeNewsWire
1 week ago
Plus Therapeutics Announces New Employment Inducement Grants
HOUSTON, March 05, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that on February 28, 2025, it granted option awards to Dr. Michael Rosol, the Company's new Chief Development Officer. The Company agreed to grant these equity awards to Dr. Rosol to induce him to commence employment with the Company.
Neutral
GlobeNewsWire
1 week ago
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the pricing of a private placement with gross proceeds to the Company expected to be approximately $15.0 million. “This financing coupled with ongoing grant support strengthens our ability to rapidly advance our CNS cancer therapies,” said Marc H.
Neutral
GlobeNewsWire
2 weeks ago
Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
AUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, having determined an RP2D. The ReSPECT-LM single-dose escalation trial assessed the safety, tolerability, and potential efficacy of intrathecally administered Rhenium (186Re) Obisbemeda in patients with leptomeningeal metastases (LM).
Neutral
GlobeNewsWire
2 weeks ago
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
Russell Bradley Named President & General Manager of CNSide Dr. Marc Hedrick, Rick Hawkins, and Russell Bradley Join CNSide Board of Directors Dr. Jonathan Stein Appointed CNSide Medical Director AUSTIN, Texas, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that is has appointed Mr. Russell Bradley as the President and General Manager of its wholly-owned subsidiary, CNSide Diagnostics, LLC (“CNSide”).
Neutral
GlobeNewsWire
3 weeks ago
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
AUSTIN, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced the appointment of Michael Rosol, Ph.D., as Chief Development Officer.
Charts implemented using Lightweight Charts™